Wu Tsai-Ming, Liu Shu-Ting, Chen Ssu-Yu, Chen Gunng-Shinng, Wu Chia-Chun, Huang Shih-Ming
Department of Biochemistry, National Defense Medical Center, Taipei City, Taiwan.
Department of Dentistry of Tri-service General Hospital, School of Dentistry, National Defense Medical Center, Taipei City, Taiwan.
Front Oncol. 2020 Sep 2;10:1483. doi: 10.3389/fonc.2020.01483. eCollection 2020.
In recent years, L-ascorbic acid (L-AA), or vitamin C, has been attracting attention as a potential anticancer drug that mediates hydrogen peroxide-induced oxidation and ten-eleven translocation 2-catalyzed DNA demethylation. However, the precise mechanism by which L-AA acts remains unclear. We examined the cytotoxic effects of L-AA or sodium ascorbate in human cervical carcinoma cells by assessing cell viability, expression of cell cycle-related mRNAs and proteins, and mitochondrial functions, and by performing flow cytometric analyses of cell cycle profiles, apoptosis, cell proliferation, and production of reactive oxygen species (ROS). We later tested the effects of ascorbates in combination with two first-line chemotherapeutic drugs, cisplatin, and doxorubicin. At pharmacological concentrations (1-10 mM), L-AA increased ROS levels; decreased levels of several cell cycle-related proteins, including p53, p21, cyclin D1, and phosphorylated histone 3 at serine residue 10; induced DNA damage, as indicated by changes in γH2A.x; decreased levels of the anti-oxidative transcription factor Nrf2; and increased levels of catalase, superoxide dismutase 1, and endoplasmic reticulum stress-related indicators, such as the p-eIF2α/eIF2α ratio and CHOP levels. L-AA also promoted cell proliferation and induced apoptosis and mitochondrial dysfunction. Finally, L-AA increased the susceptibility of HeLa cells to cisplatin and doxorubicin. These findings provide insight into how the adjustment of the cellular ROS status through L-ascorbate (L-AA or sodium ascorbate) administration could potentially synergistically enhance the efficacy of cancer therapies.
近年来,L-抗坏血酸(L-AA),即维生素C,作为一种潜在的抗癌药物受到关注,它介导过氧化氢诱导的氧化和10-11易位2催化的DNA去甲基化。然而,L-AA发挥作用的确切机制仍不清楚。我们通过评估细胞活力、细胞周期相关mRNA和蛋白质的表达以及线粒体功能,并对细胞周期分布、细胞凋亡、细胞增殖和活性氧(ROS)生成进行流式细胞术分析,研究了L-AA或抗坏血酸钠对人宫颈癌细胞的细胞毒性作用。随后,我们测试了抗坏血酸盐与两种一线化疗药物顺铂和阿霉素联合使用的效果。在药理浓度(1-10 mM)下,L-AA增加了ROS水平;降低了几种细胞周期相关蛋白的水平,包括p53、p21、细胞周期蛋白D1和丝氨酸残基10处的磷酸化组蛋白3;如γH2A.x的变化所示,诱导了DNA损伤;降低了抗氧化转录因子Nrf2的水平;增加了过氧化氢酶、超氧化物歧化酶1和内质网应激相关指标的水平,如p-eIF2α/eIF2α比值和CHOP水平。L-AA还促进了细胞增殖,并诱导了细胞凋亡和线粒体功能障碍。最后,L-AA增加了HeLa细胞对顺铂和阿霉素的敏感性。这些发现为通过给予L-抗坏血酸盐(L-AA或抗坏血酸钠)调节细胞ROS状态如何可能协同增强癌症治疗疗效提供了见解。